Drug intelligence / Profile preview

VRDN-292

Development stage: Unknown
Lead developer: Viridian Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

VRDN-292 is an investigational, half-life-extended monoclonal antibody designed to target the thyroid-stimulating hormone receptor (TSHR). Developed by Viridian Therapeutics, it is formulated for subcutaneous administration via an autoinjector, with the potential for extended dosing intervals to reduce patient treatment burden. VRDN-292 is being developed for the treatment of Graves' disease and thyroid eye disease (TED). The company expects to initiate a Phase 1 clinical trial in patients with Graves' disease in the fourth quarter of 2026.

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on VRDN-292.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRDN-292.